FRANKLIN, Mass., May 21 /PRNewswire-FirstCall/ -- PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate RenalGuard® at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend this event.
In addition, PLC will hold its first international distributor meeting, including a presentation on the status of the MYTHOS investigator-sponsored clinical trial by Dr. Antonio Bartorelli, one of the two principal investigators of the trial.
Mark R. Tauscher, president and chief executive officer of PLC Systems, said, “EuroPCR is one of the premier international cardiovascular events of the year. Since RenalGuard could provide an important solution for patients with diminished kidney function undergoing cardiac imaging procedures, this conference gives us a strong opportunity to meet with global knowledge leaders, current and potential customers, and current and potential distributors. Our first international distributor meeting, to be held in concert with EuroPCR, provides us with an important opportunity to further educate our distribution partners about the latest scientific findings on RenalGuard’s safety and efficacy, which we hope accelerates adoption of RenalGuard in the countries where it is now being marketed.”
PLC recently received Notices of Allowance for four of PLC’s patent applications associated with its RenalGuard technology from the U.S. Patent and Trademark Office. The company has distribution agreements covering Austria; Croatia; Russia; Belgium; the Netherlands; Luxembourg; all of the former Soviet Socialist Republic nations; Portugal; New Zealand; Portugal; China and Taiwan; Italy; Spain; Monaco; Pakistan and Bangladesh.
About PLC Systems Inc.
PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Massachusetts, PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. PLC’s newest product, RenalGuard, is approved for sale in the EU as a general fluid balancing device. Additional company information can be found at www.plcmed.com.
This press release contains “forward-looking” statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may be unable to raise capital necessary to continue our operations, we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, the current clinical trials in Italy and the planned future U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if these clinical trials are completed, they may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the “Forward Looking Statements” section of our Annual Report on Form 10-K for the year ended December 31, 2009,and our other SEC reports.
PLC Systems, PLC Medical Systems, PLC, CO2 Heart Laser, and RenalGuard are trademarks of PLC Systems Inc.
Contact: Mary T. Conway | |
Conway Communications | |
617-244-9682 | |
SOURCE PLC Systems
